Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines

Summary This article summarizes recommendations reached following a systematic literature review and expert consensus on the diagnosis and management of cutaneous squamous cell carcinomas in people with epidermolysis bullosa. The guidelines are intended to help inform decision making by clinicians d...

Full description

Saved in:
Bibliographic Details
Published in:British journal of dermatology (1951) Vol. 174; no. 1; pp. 56 - 67
Main Authors: Mellerio, J.E., Robertson, S.J., Bernardis, C., Diem, A., Fine, J.D., George, R., Goldberg, D., Halmos, G.B., Harries, M., Jonkman, M.F., Lucky, A., Martinez, A.E., Maubec, E., Morris, S., Murrell, D.F., Palisson, F., Pillay, E.I., Robson, A., Salas-Alanis, J.C., McGrath, J.A.
Format: Journal Article
Language:English
Published: England Blackwell Publishing Ltd 01-01-2016
Oxford University Press
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary This article summarizes recommendations reached following a systematic literature review and expert consensus on the diagnosis and management of cutaneous squamous cell carcinomas in people with epidermolysis bullosa. The guidelines are intended to help inform decision making by clinicians dealing with this complex complication of a devastating disease. What's already known about this topic? Some subtypes of epidermolysis bullosa (EB), particularly severe generalized recessive dystrophic EB, are associated with the development of mucocutaneous squamous cell carcinomas (SCCs). These tumours behave aggressively and are a leading cause of morbidity and mortality in at‐risk patients with EB. What does this study add? These guidelines will assist clinicians in the diagnosis, management and staging of EB‐associated cutaneous SCCs based on available evidence and expert consensus. They highlight the importance of a holistic multidisciplinary approach to the management of EB‐associated SCCs, where patient involvement in decision making is paramount. Linked Comment: Krupiczojc and O’Toole. Br J Dermatol 2016; 174: 15.
Bibliography:ark:/67375/WNG-T3CV5JRN-8
ArticleID:BJD14104
istex:396071C4C1C6E36F003B4E099C6C1393167728C0
SourceType-Scholarly Journals-1
ObjectType-Feature-4
ObjectType-Undefined-1
content type line 23
ObjectType-Review-2
ObjectType-Article-3
ISSN:0007-0963
1365-2133
DOI:10.1111/bjd.14104